Rxo (RXO) Cost of Revenue (2021 - 2026)

Rxo (RXO) has 6 years of Cost of Revenue data on file, last reported at $1.2 billion in Q1 2026.

• Quarterly Cost of Revenue rose 1.56% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 billion (up 15.18% YoY) and the FY2025 annual result came in at $4.6 billion, up 29.34% from the prior year.
• Cost of Revenue retreated to $1.2 billion in Q1 2026, from $1.2 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $1.4 billion in Q4 2024 to a low of $699.0 million in Q1 2024.
• A 5-year average of $937.5 million and a median of $857.0 million in 2022 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2023 — Cost of Revenue retreated 25.66% — and 2024, when it jumped 82.64%.
• Tracing RXO's Cost of Revenue over 5 years: stood at $842.0 million in 2022, then fell by 11.76% to $743.0 million in 2023, then soared by 82.64% to $1.4 billion in 2024, then declined by 11.35% to $1.2 billion in 2025, then slipped by 2.66% to $1.2 billion in 2026.
• The last three Cost of Revenue figures came in at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.